Nucana Plc ADR (NCNA)

$0.05 0.00 (-5.13%)
Market Cap 326,000.00
Revenue (ttm) 0.00
Net Income (ttm) -24.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 43,427,902
Avg Vol 182,733,531
Day's Range N/A - N/A
Shares Out 6.08M
Stochastic %K 3%
Beta 1.42
Analysts Strong Buy
Price Target $25.00

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 13 1357 1111
Address:
3 Lochside Way, Edinburgh, United Kingdom
Flipdinero101
Flipdinero101 Jul. 6 at 6:30 PM
$NCNA
0 · Reply
Flipdinero101
Flipdinero101 Jul. 6 at 6:29 PM
$NCNA
0 · Reply
Flipdinero101
Flipdinero101 Jul. 6 at 2:45 PM
$NCNA Not financial advice… Bullish!! https://x.com/ethel_stocks/status/1941850368247525868?s=12
1 · Reply
_Schlaubi_
_Schlaubi_ Jul. 6 at 10:09 AM
$NCNA Final Thoughts: NCNA is not guaranteed to squeeze, but the technicals strongly suggest the potential is there. With short interest over 80 percent, a tiny float, and high borrow costs, this is one of the most asymmetric short squeeze setups on the market right now. All it needs is a spark. This is a speculative setup and not financial advice. Always do your own research and never invest more than you can afford to lose.
0 · Reply
_Schlaubi_
_Schlaubi_ Jul. 6 at 10:09 AM
$NCNA Potential Catalysts: • Retail momentum building across trading forums • General biotech sector movement • Technical break above resistance levels (such as 6 cents) • Pre-market strength or early volume surge on Monday Things to Watch Monday Morning: • Pre-market volume and price action • Short volume percentage during market hours • Borrow availability dropping or fee increasing • Sudden spikes in call option volume (if available) • Any positive biotech news or press releases Trade Plan (For Discussion Only): • Ideal entry: Under 5 cents • First target: 7.5 cents • Second target: 10 cents or higher if momentum is strong • Suggested stop loss: Around 4.5 cents to limit downside • Risk management is critical due to high volatility
0 · Reply
_Schlaubi_
_Schlaubi_ Jul. 6 at 10:08 AM
$NCNA Why This Matters: 1. Extremely High Short Interest: Anything above 20 to 30 percent is considered heavily shorted. NCNA sits at over 80 percent, which is exceptionally rare and highly volatile. 2. Very Small Float: With under 6 million shares freely tradable, even moderate buying pressure can cause large price swings. This is exactly the kind of setup that led to historic moves in previous low-float squeezes. 3. Borrow Fee is Punitive: Shorts are paying up to 45 percent APR just to hold their positions. If price starts rising, they have strong incentive to cover quickly and avoid further losses. 4. High Volume Trading: On multiple days, trading volume has exceeded the float. That’s a major signal that the stock is in play and interest is building. 5. Oversold RSI: Relative Strength Index is around 38, which is near oversold territory. This means downside may be limited and any positive momentum could trigger a rebound.
0 · Reply
_Schlaubi_
_Schlaubi_ Jul. 6 at 10:07 AM
$NCNA Key Stats (as of mid-June 2025): • Short interest: 4.61 million shares shorted • Estimated float: approximately 5.7 million shares • Short float percentage: approximately 81 percent • Borrow fee: between 44 to 46 percent APR (extremely high) • Price range: currently trading around 5 to 5.5 cents • Average daily volume: 37 to 43 million shares • Days to cover: less than 0.2 (indicates shorts could get squeezed quickly if momentum builds)
0 · Reply
_Schlaubi_
_Schlaubi_ Jul. 6 at 10:06 AM
$NCNA 81 Percent Short Float, 45 Percent Borrow Fee, Micro Float – A Squeeze May Be Brewing Overview: NuCana plc (ticker: NCNA) is shaping up to be one of the most shorted and overlooked micro-cap setups going into Monday. With short interest over 80 percent, a very low float, and rising retail attention, this stock has all the technical ingredients for a potential short squeeze. Below is a data-backed breakdown.
1 · Reply
SteadyUptrend
SteadyUptrend Jul. 6 at 2:42 AM
PMAX is setting up for a big move ahead, The volume last week indicates something is def brewing. 3M bids appearing is no coincidence. With high short interest and shorts only have 11.5 days to cover, this could really squeeze. $NCNA $HCTI $FFAI $CURR
1 · Reply
ThatDudeWithNoMoney
ThatDudeWithNoMoney Jul. 6 at 12:45 AM
$LRHC $HCTI $WLGS $NCNA ⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️
0 · Reply
Latest News on NCNA
NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Jun 2, 2025, 4:01 PM EDT - 4 weeks ago

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mar 20, 2025, 4:01 PM EDT - 3 months ago

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Feb 10, 2025, 7:00 AM EST - 5 months ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 25, 2024, 7:00 AM EST - 7 months ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Nov 11, 2024, 7:00 AM EST - 8 months ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Oct 4, 2024, 12:03 PM EDT - 9 months ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

Sep 25, 2024, 4:01 PM EDT - 10 months ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Sep 14, 2024, 3:01 AM EDT - 10 months ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 29, 2024, 4:01 PM EDT - 11 months ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 15, 2024, 4:01 PM EDT - 11 months ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Global Healthcare Conference

May 30, 2024, 8:36 AM EDT - 1 year ago

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 21, 2024, 8:00 AM EDT - 1 year ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 16, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 1, 2024, 4:01 PM EDT - 1 year ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Apr 9, 2024, 4:30 PM EDT - 1 year ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

NuCana Announces Plan to Implement ADS Ratio Change

Mar 27, 2024, 4:30 PM EDT - 1 year ago

NuCana Announces Plan to Implement ADS Ratio Change

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Mar 20, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 1 year ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

NuCana: Potential Turnaround In 2024 But Risky

Jan 3, 2024, 2:39 AM EST - 1 year ago

NuCana: Potential Turnaround In 2024 But Risky

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 16, 2023, 4:01 PM EST - 1 year ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 10, 2023, 4:01 PM EST - 1 year ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

NuCana to Present at the Jefferies London Healthcare Conference

Nov 8, 2023, 4:01 PM EST - 1 year ago

NuCana to Present at the Jefferies London Healthcare Conference

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Nov 1, 2023, 4:01 PM EDT - 1 year ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 16, 2023, 7:00 AM EDT - 1 year ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 1 year ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 1 year ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 16, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 2 years ago

NuCana to Present at the Jefferies Healthcare Conference

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 17, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Receipt of Nasdaq Notice

May 12, 2023, 4:01 PM EDT - 2 years ago

NuCana Announces Receipt of Nasdaq Notice

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 14, 2023, 8:00 AM EDT - 2 years ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Apr 4, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Mar 24, 2023, 4:30 PM EDT - 2 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

NuCana to Participate in Two Upcoming Investor Conferences

Feb 28, 2023, 8:00 AM EST - 2 years ago

NuCana to Participate in Two Upcoming Investor Conferences

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

Jan 8, 2023, 4:30 AM EST - 2 years ago

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

NuCana Announces Receipt of NASDAQ Notice

Jan 6, 2023, 4:01 PM EST - 2 years ago

NuCana Announces Receipt of NASDAQ Notice

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 16, 2022, 4:01 PM EST - 2 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Oct 26, 2022, 7:00 AM EDT - 2 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

NuCana: An Intriguing 'Sum Of The Parts' Story

Sep 22, 2022, 3:40 PM EDT - 3 years ago

NuCana: An Intriguing 'Sum Of The Parts' Story

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Sep 12, 2022, 10:45 AM EDT - 3 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Sep 6, 2022, 8:00 AM EDT - 3 years ago

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

NuCana to Participate in Citi's 17th Annual BioPharma Conference

Aug 31, 2022, 8:00 AM EDT - 3 years ago

NuCana to Participate in Citi's 17th Annual BioPharma Conference

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 17, 2022, 4:01 PM EDT - 3 years ago

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Jul 13, 2022, 6:00 AM EDT - 3 years ago

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Why NuCana Shares Are Rising Today?

Jul 11, 2022, 1:52 PM EDT - 3 years ago

Why NuCana Shares Are Rising Today?

German Court Rules that Gilead's Sofosbuvir Infringes NuCana's ‘190 Patent

Jul 11, 2022, 8:00 AM EDT - 3 years ago

German Court Rules that Gilead's Sofosbuvir Infringes NuCana's ‘190 Patent

NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

Jun 10, 2022, 7:00 AM EDT - 3 years ago

NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

Jun 2, 2022, 4:01 PM EDT - 3 years ago

NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

NuCana to Participate in the 2022 Jefferies Healthcare Conference

Jun 1, 2022, 4:01 PM EDT - 3 years ago

NuCana to Participate in the 2022 Jefferies Healthcare Conference

NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update

Apr 27, 2022, 4:01 PM EDT - 3 years ago

NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update

Flipdinero101
Flipdinero101 Jul. 6 at 6:30 PM
$NCNA
0 · Reply
Flipdinero101
Flipdinero101 Jul. 6 at 6:29 PM
$NCNA
0 · Reply
Flipdinero101
Flipdinero101 Jul. 6 at 2:45 PM
$NCNA Not financial advice… Bullish!! https://x.com/ethel_stocks/status/1941850368247525868?s=12
1 · Reply
_Schlaubi_
_Schlaubi_ Jul. 6 at 10:09 AM
$NCNA Final Thoughts: NCNA is not guaranteed to squeeze, but the technicals strongly suggest the potential is there. With short interest over 80 percent, a tiny float, and high borrow costs, this is one of the most asymmetric short squeeze setups on the market right now. All it needs is a spark. This is a speculative setup and not financial advice. Always do your own research and never invest more than you can afford to lose.
0 · Reply
_Schlaubi_
_Schlaubi_ Jul. 6 at 10:09 AM
$NCNA Potential Catalysts: • Retail momentum building across trading forums • General biotech sector movement • Technical break above resistance levels (such as 6 cents) • Pre-market strength or early volume surge on Monday Things to Watch Monday Morning: • Pre-market volume and price action • Short volume percentage during market hours • Borrow availability dropping or fee increasing • Sudden spikes in call option volume (if available) • Any positive biotech news or press releases Trade Plan (For Discussion Only): • Ideal entry: Under 5 cents • First target: 7.5 cents • Second target: 10 cents or higher if momentum is strong • Suggested stop loss: Around 4.5 cents to limit downside • Risk management is critical due to high volatility
0 · Reply
_Schlaubi_
_Schlaubi_ Jul. 6 at 10:08 AM
$NCNA Why This Matters: 1. Extremely High Short Interest: Anything above 20 to 30 percent is considered heavily shorted. NCNA sits at over 80 percent, which is exceptionally rare and highly volatile. 2. Very Small Float: With under 6 million shares freely tradable, even moderate buying pressure can cause large price swings. This is exactly the kind of setup that led to historic moves in previous low-float squeezes. 3. Borrow Fee is Punitive: Shorts are paying up to 45 percent APR just to hold their positions. If price starts rising, they have strong incentive to cover quickly and avoid further losses. 4. High Volume Trading: On multiple days, trading volume has exceeded the float. That’s a major signal that the stock is in play and interest is building. 5. Oversold RSI: Relative Strength Index is around 38, which is near oversold territory. This means downside may be limited and any positive momentum could trigger a rebound.
0 · Reply
_Schlaubi_
_Schlaubi_ Jul. 6 at 10:07 AM
$NCNA Key Stats (as of mid-June 2025): • Short interest: 4.61 million shares shorted • Estimated float: approximately 5.7 million shares • Short float percentage: approximately 81 percent • Borrow fee: between 44 to 46 percent APR (extremely high) • Price range: currently trading around 5 to 5.5 cents • Average daily volume: 37 to 43 million shares • Days to cover: less than 0.2 (indicates shorts could get squeezed quickly if momentum builds)
0 · Reply
_Schlaubi_
_Schlaubi_ Jul. 6 at 10:06 AM
$NCNA 81 Percent Short Float, 45 Percent Borrow Fee, Micro Float – A Squeeze May Be Brewing Overview: NuCana plc (ticker: NCNA) is shaping up to be one of the most shorted and overlooked micro-cap setups going into Monday. With short interest over 80 percent, a very low float, and rising retail attention, this stock has all the technical ingredients for a potential short squeeze. Below is a data-backed breakdown.
1 · Reply
SteadyUptrend
SteadyUptrend Jul. 6 at 2:42 AM
PMAX is setting up for a big move ahead, The volume last week indicates something is def brewing. 3M bids appearing is no coincidence. With high short interest and shorts only have 11.5 days to cover, this could really squeeze. $NCNA $HCTI $FFAI $CURR
1 · Reply
ThatDudeWithNoMoney
ThatDudeWithNoMoney Jul. 6 at 12:45 AM
$LRHC $HCTI $WLGS $NCNA ⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️
0 · Reply
gioentaly
gioentaly Jul. 5 at 9:08 PM
$NCNA
0 · Reply
cycloon
cycloon Jul. 5 at 7:32 PM
$NCNA NuCana Short Interest Data NuCana (NCNA) has a short interest of 4.61 million shares, representing 80.88% of the float (the number of shares available for trading by the public). This marks a 66.43% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 37.72 million shares to cover all short positions. Current Short Interest4,610,000 shares Previous Short Interest2,770,000 shares Change Vs. Previous Month+66.43% Dollar Volume Sold Short$529.69 thousand Short Interest Ratio0.0 Days to Cover Last Record DateJune 15, 2025 Outstanding Shares6,080,000 shares Float Size5,700,000 shares Short Percent of Float80.88% Today's Trading Volume43,427,988 shares Average Trading Volume37,718,668 shares Today's Volume Vs. Average115% Skip Charts & View Short Interest History Short Interest ChartDays to Cover ChartShort Percent of Float Chart
1 · Reply
PaulLaurent
PaulLaurent Jul. 5 at 7:03 PM
🔄📉 Oversold Small Caps Update 🧪🔄 $LRHC $IXHL $HCTI $WLGS $NCNA
1 · Reply
CATATOM
CATATOM Jul. 5 at 2:35 PM
$NCNA As of the latest data heading into Monday, July 7, 2025, NuCana plc (NCNA) is absolutely one of the most elevated short squeeze candidates in the entire U.S. market—if not the top contender.
2 · Reply
Jey74
Jey74 Jul. 5 at 7:51 AM
$NCNA Okay, you are right indeed. I learned something new again, thank you. Sorry.
0 · Reply
OlgumQuePasa
OlgumQuePasa Jul. 5 at 7:37 AM
$NCNA I’ve shared my data. LS, Gettex, and Tradegate all pull from Nasdaq! When Nasdaq is closed, the spread increases – that’s why it looks like the stock is at €0.36. But you don’t get that, because you don’t want to get it. You’d rather confuse people or play pretend like you’re some kind of trader.
1 · Reply
OlgumQuePasa
OlgumQuePasa Jul. 5 at 7:26 AM
$NCNA I’ll tell you again – stop talking bullshit! The reason for the wide spread is that the home exchange has been closed for a day and a half! You might be spreading uncertainty with your lies, but you know damn well that, apart from your joy in lying, you won’t achieve anything.
1 · Reply
OlgumQuePasa
OlgumQuePasa Jul. 5 at 7:19 AM
$NCNA Are you so broke that you already have to start talking crap? The spread is 2 cents! By Wednesday, it’ll be back at €0.46 or €0.47.
1 · Reply
OlgumQuePasa
OlgumQuePasa Jul. 5 at 7:18 AM
$NCNA Bullshit☺️ The Spread is Big! No Volumen and NASDAQ ist closed
0 · Reply
Brachina
Brachina Jul. 5 at 6:43 AM
$NCNA https://www.tradegate.de/orderbuch.php?isin=US67022C2052 Tradegate is the important german stock exchange
1 · Reply
th3_fail_k1ng
th3_fail_k1ng Jul. 5 at 3:36 AM
$NCNA
0 · Reply
Jey74
Jey74 Jul. 4 at 11:44 PM
$NCNA ❗️BREAKING❗️NuCana has closed at 0.036 € / 0,042 $ (-22.58%) on the German Stock Exchange Gettex. We are approaching a critical resistance zone, and there is a possibility that prices could fall to 0.035 $. Given the upcoming Nasdaq Rule 5810(c)(3)(A)(iii, which comes into effect on Monday, NuCana must act urgently. If the closing price remains at 0.10 $ or less for ten consecutive trading days, a delisting could be imminent. The company has until December 15, 2025, to meet compliance requirements. In conclusion, time is of the essence. NuCana faces significant challenges, and mistakes cannot be afforded. Monday could be crucial for the company's future. This is my personal analysis and assessment of the current situation.
3 · Reply